Develops therapies for neurodegenerative diseases using a proprietary blood-brain-barrier delivery platform.
Develops therapies for neurodegenerative diseases using a proprietary blood-brain-barrier delivery platform.
Revenue so far has come from partners' upfront and milestone payments rather than product sales, with Takeda and Biogen among those sharing the cost of its drugs; the rest of its funding comes from selling shares to investors.
Moat: narrow (IP / patents, process know-how). Proprietary Transport Vehicle platform for crossing the blood-brain barrier, licensed to major pharma partners.
Headquarters: South San Francisco, California, US · Founded: 2013 · Employees: 503
Size Denali Therapeutics (DNLI) is a United States Health Care company (Biotechnology) with a market value of $2.95B, the 1553rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $18.40 on 18 Nov 2026.
Performance Over six months the shares fell 2.3%, against -2.9% for the median peer and -2.2% for the United States market (cap-weighted) — 11th highest of 21 in its peer set.
Growth The operating margin is -2,488.1% (peer median 5.2%).
Valuation It trades at 115.4× enterprise value to sales against a peer median of 6.0× (2nd most expensive of 18).
Capital Return on invested capital runs 104.8 points below its cost of capital (10.4% WACC).
Short interest Short interest is 9.2% of the free float (30 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $21.4M | $0 | $0 | $331M | $108M |
| Revenue growth | — | — | -100% | +205% | — |
| Gross profit | $4.58M | -$14.8M | -$7.79M | $314M | $101M |
| EBITDA | -$515M | -$541M | -$494M | -$180M | -$334M |
| Net income | -$314M | -$513M | -$423M | -$145M | -$326M |
| Free cash flow | -$450M | -$422M | -$364M | -$371M | -$263M |
| Capital expenditure | $41.8M | $9.50M | $15.9M | $12.9M | $17.8M |
| Total debt | $35.2M | $42.3M | $54.3M | $52.2M | $60.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Denali Therapeutics DNLI | $2.95B | -2% | n/a | -2,488% | 115.4× | n/a |
| Biogen BIIB | $37.2B | +34% | +2% | 17% | 4.4× | 10.1% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 15.6× | 6.5% |
| Alector ALEC | $383M | +21% | +151% | 25% | 1.5× | n/a |
| Ionis Pharmaceuticals IONS | $4.56B | -64% | -1% | -59% | 5.0× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DNLI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.8% | -4.6% | 10th highest of 21 |
| 6-month return | -2.3% | -2.9% | 11th highest of 21 |
| Distance from 52-week high | -32.6% | -29.3% | 10th lowest of 21 |
| Operating margin | -2,488.1% | 5.2% | 2nd lowest of 18 |
| EV / Sales | 115.4× | 6.0× | 2nd most expensive of 18 |
| ROIC minus cost of capital | -104.8 pp | -5.7 pp | 2nd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Denali Therapeutics DNLI | United States | $2.95B | -2% | n/a | -2,488% | 115.4× | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.94B | +68% | +37% | 21% | 13.2× | n/a | n/a |
| Dyne Therapeutics DYN | United States | $2.97B | -10% | n/a | n/a | n/a | n/a | n/a |
| Telix Pharmaceuticals TLX.AX | Australia | $2.99B | -2% | +27% | -1% | 3.8× | n/a | n/a |
| ADMA Biologics ADMA | United States | $3.01B | +58% | +6% | 45% | 6.0× | -0.8% | +64.6% |
| XtalPi 2228.HK | Hong Kong | $2.87B | -34% | +4% | -127% | 21.3× | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.82B | +23% | -8% | 18% | 2.6× | -4.3% | +27.4% |
| Xeris Biopharma XERS | United States | $3.10B | +173% | +38% | 13% | 8.7× | 29.5% | +70.2% |
| Zai Lab 9688.HK | Hong Kong | $2.79B | +23% | 0% | -63% | 5.4× | n/a | n/a |
| Virbac VIRP.PA | France | $3.20B | -4% | +4% | 15% | 2.1× | 5.8% | +9.4% |
| Hualan Biological Engineering 002007.SZ | China | $3.20B | -17% | -11% | 17% | 5.3× | 15.8% | -1.8% |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.72B | -7% | +20% | -3% | 5.9× | n/a | n/a |
| HLB 028300.KS | South Korea | $2.69B | -49% | +26% | -96% | 38.7× | n/a | n/a |
| MBX Biosciences MBX | United States | $2.65B | +70% | n/a | n/a | n/a | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.30B | +7% | n/a | n/a | n/a | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.32B | -25% | -54% | -6,983% | 6,626.2× | n/a | n/a |
| Xencor XNCR | United States | $2.58B | +204% | +34% | -73% | 11.7× | n/a | n/a |
| Xiamen Amoytop Biotech 688278.SS | China | $2.56B | -27% | +18% | 27% | 4.3× | -0.6% | +36.0% |
| Iovance Biotherapeutics IOVA | United States | $3.46B | +111% | +51% | -61% | 8.3× | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.47B | -13% | -13% | 21% | 4.5× | 2.2% | +12.5% |
| Walvax Biotechnology 300142.SZ | China | $2.48B | -26% | -23% | 5% | 9.4× | 29.5% | -3.8% |